1. Home
  2. OZ vs LUNG Comparison

OZ vs LUNG Comparison

Compare OZ & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belpointe PREP LLC Units

OZ

Belpointe PREP LLC Units

HOLD

Current Price

$46.61

Market Cap

196.2M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.53

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OZ
LUNG
Founded
2020
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.2M
57.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
OZ
LUNG
Price
$46.61
$1.53
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
6.2K
393.9K
Earning Date
05-19-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$9,187,000.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
243.44
8.01
52 Week Low
$47.00
$1.13
52 Week High
$69.00
$3.88

Technical Indicators

Market Signals
Indicator
OZ
LUNG
Relative Strength Index (RSI) 27.50 53.50
Support Level N/A $1.36
Resistance Level $51.50 $1.64
Average True Range (ATR) 0.80 0.12
MACD -0.09 0.01
Stochastic Oscillator 0.00 57.78

Price Performance

Historical Comparison
OZ
LUNG

About OZ Belpointe PREP LLC Units

Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: